We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Antibiotic Targets Chronic Pain Memory Traces

By HospiMedica staff writers
Posted on 18 Jun 2007
A new study has identified a drug that controls persistent nerve pain by targeting the prefrontal cortex, the part of the brain that experiences the emotional suffering of pain.

Researchers at Northwestern University (Chicago, IL, USA) placed rats in a two-compartment chamber--one side well-lit, the other dark. More...
When the rats were in their preferred dark side, scientists mechanically stimulated their sensitive limbs. The rats did not like that and bolted into the bright chamber, where they remained. The scientists then took the same rats and treated them with D-Cycloserine. Again, scientists stimulated the rats' sensitive limbs; this time, however, the rats remained in the dark chamber.

The results indicated that while the physical pain appeared to be reduced 30%, the rats' emotional suffering completely disappeared. The drug also had long-term benefits; animals appeared to be pain-free 30 days after the last dose of a 30-day regime of D-Cycloserine. The study was published in the online edition of Pain, the journal of the International Association for the Study of Pain (IASP).

"In some ways, you can think of chronic pain as the inability to turn off the memory of the pain,” said lead author Dr. Vania Apkarian, a professor of physiology and anesthesiology. "What's exciting is that we now may be relieving what has clinically been the most difficult to treat--the suffering or the emotional component of pain.”

D-Cycloserine, an antibiotic that is a partial agonist at the glycine modulatory site of the glutamatergic N-methyl-D-aspartate (NMDA) receptor site, has been used to treat phobic behavior over the past decade, and has also been found to control nerve pain resulting from chemotherapy.


Related Links:
Northwestern University

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.